Increased utilization of GLP-1 receptor agonists and SGLT2 inhibitors
1 paper2 findings
- In silico1
Outcomes
1Alzheimer's disease and related dementias incidence
downin silico1
1 study
Alzheimer's disease and related dementias incidence
downin silico1
Increased utilization of GLP-1 receptor agonists and SGLT2 inhibitors decrease alzheimer's disease and related dementias incidence in silico (76,000–201,000 ADRD cases averted over 10 years).
“Over 10 years, utilization of GLP1s and SGLT2s by people with diabetes and HbA1c > 7 could avert 76,000-201,000 ADRD cases.”
In silicoAmericans with diabetes and HbA1c > 7; dynamic microsimulation of increased utilization10 years
Alzheimer's & dementia : the journal of the Alzheimer's Association1 Oct 2026
Associations
1Alzheimer's disease and related dementias risk
downin silico1
1 study
Alzheimer's disease and related dementias risk
downin silico1
Increased utilization of GLP-1 receptor agonists and SGLT2 inhibitors lower the risk of alzheimer's disease and related dementias risk in silico.
“The risk reduction is largest for Black and Hispanic individuals and individuals with HbA1c > 8.”
In silicoLargest modeled reduction among Black and Hispanic individuals and individuals with HbA1c > 810 years
Alzheimer's & dementia : the journal of the Alzheimer's Association1 Oct 2026